Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and AstraZeneca (NYSE:AZN) are among those companies with late stage drugs in trials that specifically target genetic mutations. Both BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s BMN-673, which is in phase 3 trials, and Astra’s Olaparib, which may get the EU’s go-ahead in ovarian cancer this year, address a mutation of the BRCA 1 and BRCA 2 gene that is often associated with breast … Continue reading Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)

Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)

Geron Corp. (NASDAQ:GERN) stock had its “positive” rating reiterated by equities research analysts at Wells Fargo & Co. in a research note issued to investors on Thursday, American Banking News.com reports.Geron Corporation (NASDAQ:GERN) stock performance was -2.73% in last session and finished the day at $1.78. Traded volume was 7,214,860 million shares in the last session and the average volume of the stock remained 5.57 … Continue reading Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume was 4.36million shares in the last session and the average … Continue reading Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) announced that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014, at 4:30 p.m. ET. Novavax, Inc. (NASDAQ:NVAX) dropped -5.02 percent to $6.05 yesterday on volume of 4.36 million shares. The intra-day range of the stock was $5.86 to $6.47. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of … Continue reading NASDAQ Losers: Plug Power Inc (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), FireEye Inc (NASDAQ:FEYE), Children’s Place Retail Stores (NASDAQ:PLCE)

Pfizer Inc. (NYSE:PFE) has begun testing an over-the-counter version of Lipitor, the blockbuster drug that has plumped up the pharmaceutical giant’s coffers for more than a decade. Pfizer Inc. (NYSE:PFE) stock performance was 2.22% in last session and finished the day at $32.69. Traded volume was 26,325,091 million shares in the last session and the average volume of the stock remained 26.27 million shares. The … Continue reading Healthcare Sector Most Active: Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Boston Scientific Corporation (NYSE:BSX), Dendreon Corporation (NASDAQ:DNDN)